Role of G protein-coupled receptor kinases 2 and 3 in μ-opioid receptor desensitization and internalization

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 347-356

  Lowe, Janet D ^a   Sanderson, Helen S ^a   Cooke, Alexandra E ^a   Ostovar, Mehrnoosh ^c   Tsisanova, Elena ^a   Withey, Sarah L ^a   Chavkin, Charles ^b   Husbands, Stephen M ^c   Kelly, Eamonn ^a   Henderson, Graeme ^a   Bailey, Chris P ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; MU OPIATE RECEPTOR;

ANIMAL; C57BL MOUSE; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; LOCUS CERULEUS; MALE; METABOLISM; MOUSE; RAT; WISTAR RAT;

ANIMALS; BENZAMIDES; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 3; HEK293 CELLS; HUMANS; LOCUS COERULEUS; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; RECEPTORS, OPIOID, MU;

EID: 84939806217     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.098293     Document Type: Article

References (40)

1. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zastrow M, Grandy DK, and Williams JT (2002) mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 22:5769-5776.
2. Arttamangkul S, Lau EK, Lu HW, and Williams JT (2012) Desensitization and trafficking of μ-opioid receptors in locus ceruleus neurons: modulation by kinases. Mol Pharmacol 81:348-355.
3. Bailey CP, Couch D, Johnson E, Griffiths K, Kelly E, and Henderson G (2003) Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine. J Neurosci 23:10515-10520.
4. Bailey CP, Kelly E, and Henderson G (2004) Protein kinase C activation enhances morphine-induced rapid desensitization of mu-opioid receptors in mature rat locus ceruleus neurons. Mol Pharmacol 66:1592-1598.
5. Bailey CP, Llorente J, Gabra BH, Smith FL, Dewey WL, Kelly E, and Henderson G (2009a) Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci 29:307-318.
6. Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Roberts L, McArdle CA, Smith FL, Dewey WL, and Kelly E et al. (2009b) Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 158:157-164.
7. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315.
8. Black JW, Leff P, Shankley NP, and Wood J (1985) An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84:561-571.
9. Chen YJ, Oldfield S, Butcher AJ, Tobin AB, Saxena K, Gurevich VV, Benovic JL, Henderson G, and Kelly E (2013) Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor. J Neurochem 124:189-199.
10. Connor M, Osborne PB, and Christie MJ (2004) Mu-opioid receptor desensitization: is morphine different? Br J Pharmacol 143:685-696.
11. Cruzalegui FH, Cano E, and Treisman R (1999) ERK activation induces phosphorylationof Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 18:7948-7957.
12. Dang VC, Napier IA, and Christie MJ (2009) Two distinct mechanisms mediate acute mu-opioid receptor desensitization in native neurons. J Neurosci 29:3322-3327.
13. Doll C, Konietzko J, Pöll F, Koch T, Höllt V, and Schulz S (2011) Agonist-selective patterns of μ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164:298-307.
14. Doll C, Pöll F, Peuker K, Loktev A, Glück L, and Schulz S (2012) Deciphering μ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol 167:1259-1270.
15. Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U, and Höllt V (2001) Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res 95:129-137.
16. Hastie CJ, McLauchlan HJ, and Cohen P (2006) Assay of protein kinases using radiolabeled ATP: a protocol. Nat Protoc 1:968-971.
17. Homan KT, Wu E, Cannavo A, Koch WJ, and Tesmer JJ (2014a) Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor. Molecules 19:16937-16949.
18. Homan KT, Wu E, Wilson MW, Singh P, Larsen SD, and Tesmer JJ (2014b) Structural and functional analysis of G protein-coupled receptor kinase inhibition by paroxetine and a rationally designed analog. Mol Pharmacol 85:237-248.
19. Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, Henderson G, and Dewey WL (2010) The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther 332:1127-1135.
20. Iino M, Furugori T, Mori T, Moriyama S, Fukuzawa A, and Shibano T (2002) Rational design and evaluation of new lead compound structures for selective betaARK1 inhibitors. J Med Chem 45:2150-2159.
21. Ikeda S, Keneko M, and Fujiwara S (2007) inventors, Takeda Pharmaceutical Co. Ltd., Ikeda S, Keneko M, Fujiwara S, assignees. Cardiotonic agent comprising GRK inhibitor. International patent WO 2007034846. 2007 Mar 29.
22. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, and Henderson G (2006) Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70:676-685.
23. Just S, Illing S, Trester-Zedlitz M, Lau EK, Kotowski SJ, Miess E, Mann A, Doll C, Trinidad JC, and Burlingame AL et al. (2013) Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol 83:633-639.
24. Kelly E, Bailey CP, and Henderson G (2008) Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153 (Suppl 1):S379-S388.
25. Li AH and Wang HL (2001) G protein-coupled receptor kinase 2 mediates mu-opioid receptor desensitization in GABAergic neurons of the nucleus raphe magnus. J Neurochem 77:435-444.
26. Llorente J, Lowe JD, Sanderson HS, Tsisanova E, Kelly E, Henderson G, and Bailey CP (2012) μ-Opioid receptor desensitization: homologous or heterologous? Eur J Neurosci 36:3636-3642.
27. Lohse MJ, Benovic JL, Caron MG, and Lefkowitz RJ (1990) Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specific inhibitors. J Biol Chem 265:3202-3211.
28. Manning G, Whyte DB, Martinez R, Hunter T, and Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934.
29. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, and Charlton SJ et al. (2010) μ-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756-766.
30. Mundell SJ, Luo J, Benovic JL, Conley PB, and Poole AW (2006) Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. Traffic 7:1420-1431.
31. North RA and Williams JT (1985) On the potassium conductance increased by opioids in rat locus coeruleus neurones. J Physiol 364:265-280.
32. Quillinan N, Lau EK, Virk M, von Zastrow M, and Williams JT (2011) Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone. J Neurosci 31:4434-4443.
33. Raveh A, Cooper A, Guy-David L, and Reuveny E (2010) Nonenzymatic rapid control of GIRK channel function by a G protein-coupled receptor kinase. Cell 143:750-760.
34. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, and Hochberg I et al. (2013) An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat Med 19:313-321.
35. Roskoski R, Jr (2012) ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66:105-143.
36. Shenoy SK and Lefkowitz RJ (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32:521-533.
37. Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowitz RJ, and Chavkin C (2004) G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 141:55-64.
38. Thal DM, Yeow RY, Schoenau C, Huber J, and Tesmer JJ (2011) Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol 80:294-303.
39. Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, Chuprun JK, Song J, Gao E, and Cheung JY et al. (2012) Paroxetine is a direct inhibitor of G protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 7:1830-1839.
40. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, and Christie MJ (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223-254.